Found 499 with Last Name = 'wasnaire' and Initial = 'p' 
Affinity DataKi: 2.40nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 2.70nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 2.80nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 5.20nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 6.40nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 12nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 100nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 120nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 270nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 280nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 330nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 330nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 590nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 790nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 950nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 1.10E+3nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 1.50E+3nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 1.70E+3nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 3.30E+3nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 6.80E+3nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 1.10E+4nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 1.40E+4nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
Affinity DataKi: 1.60E+5nMAssay Description:The binding properties of the test compounds on adenosine receptors were determined in binding studies with radioligands. For this purpose, membrane ...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.246nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.274nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.287nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.325nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.330nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.363nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.372nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.388nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.388nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.394nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.401nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.407nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.419nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.429nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.432nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.448nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.459nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.472nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.473nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.475nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFRβ (amino acids R561-L1106), expr...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.487nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFRβ (amino acids R561-L1106), expr...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.496nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.498nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:The identification of agonists and antagonists of the V1a and V2 vasopressin receptors from humans, rats and dogs as well as the quantification of th...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.503nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.503nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.522nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
